Robert A Avery1, Awais Mansoor2, Rabia Idrees2, Elijah Biggs2, Mohammad Ali Alsharid2, Roger J Packer2, Marius George Linguraru2. 1. From the Center for Neuroscience and Behavior (R.A.A., R.J.P.), The Gilbert Family Neurofibromatosis Institute (R.A.A., R.J.P.), the Sheikh Zayed Institute for Pediatric Surgical Innovation (A.M., E.B., M.A.A., M.G.L.), and The Brain Tumor Institute (R.J.P.), Children's National Health System; The George Washington University (R.I.); and The George Washington University School of Medicine and Health Sciences (M.G.L.), Washington, DC. averyr@email.chop.edu. 2. From the Center for Neuroscience and Behavior (R.A.A., R.J.P.), The Gilbert Family Neurofibromatosis Institute (R.A.A., R.J.P.), the Sheikh Zayed Institute for Pediatric Surgical Innovation (A.M., E.B., M.A.A., M.G.L.), and The Brain Tumor Institute (R.J.P.), Children's National Health System; The George Washington University (R.I.); and The George Washington University School of Medicine and Health Sciences (M.G.L.), Washington, DC.
Abstract
OBJECTIVE: To determine quantitative size thresholds for enlargement of the optic nerve, chiasm, and tract in children with neurofibromatosis type 1 (NF1). METHODS: Children 0.5-18.6 years of age who underwent high-resolution T1-weighted MRI were eligible for inclusion. This consisted of children with NF1 with or without optic pathway gliomas (OPGs) and a control group who did not have other acquired, systemic, or genetic conditions that could alter their anterior visual pathway (AVP). Maximum and average diameter and volume of AVP structures were calculated from reconstructed MRI images. Values above the 95th percentile from the controls were considered the threshold for defining an abnormally large AVP measure. RESULTS: A total of 186 children (controls = 82; NF1noOPG = 54; NF1+OPG = 50) met inclusion criteria. NF1noOPG and NF1+OPG participants demonstrated greater maximum optic nerve diameter and volume, optic chiasm volume, and total brain volume compared to controls (p < 0.05, all comparisons). Total brain volume, rather than age, predicted optic nerve and chiasm volume in controls (p < 0.05). Applying the 95th percentile threshold to all NF1 participants, the maximum optic nerve diameter (3.9 mm) and AVP volumes resulted in few false-positive errors (specificity >80%, all comparisons). CONCLUSIONS: Quantitative reference values for AVP enlargement will enhance the development of objective diagnostic criteria for OPGs secondary to NF1.
OBJECTIVE: To determine quantitative size thresholds for enlargement of the optic nerve, chiasm, and tract in children with neurofibromatosis type 1 (NF1). METHODS:Children 0.5-18.6 years of age who underwent high-resolution T1-weighted MRI were eligible for inclusion. This consisted of children with NF1 with or without optic pathway gliomas (OPGs) and a control group who did not have other acquired, systemic, or genetic conditions that could alter their anterior visual pathway (AVP). Maximum and average diameter and volume of AVP structures were calculated from reconstructed MRI images. Values above the 95th percentile from the controls were considered the threshold for defining an abnormally large AVP measure. RESULTS: A total of 186 children (controls = 82; NF1noOPG = 54; NF1+OPG = 50) met inclusion criteria. NF1noOPG and NF1+OPG participants demonstrated greater maximum optic nerve diameter and volume, optic chiasm volume, and total brain volume compared to controls (p < 0.05, all comparisons). Total brain volume, rather than age, predicted optic nerve and chiasm volume in controls (p < 0.05). Applying the 95th percentile threshold to all NF1participants, the maximum optic nerve diameter (3.9 mm) and AVP volumes resulted in few false-positive errors (specificity >80%, all comparisons). CONCLUSIONS: Quantitative reference values for AVP enlargement will enhance the development of objective diagnostic criteria for OPGs secondary to NF1.
Authors: Marios C Yiannakas; Claudia A M Wheeler-Kingshott; Alaine M Berry; Karyn Chappell; Andrew Henderson; Madhan Kolappan; David H Miller; Daniel J Tozer Journal: J Magn Reson Imaging Date: 2010-06 Impact factor: 4.813
Authors: Marios C Yiannakas; Ahmed T Toosy; Rhian E Raftopoulos; Raj Kapoor; David H Miller; Claudia A M Wheeler-Kingshott Journal: Invest Ophthalmol Vis Sci Date: 2013-06-21 Impact factor: 4.799
Authors: Phoebe D Lenhart; Nilesh K Desai; Beau B Bruce; Amy K Hutchinson; Scott R Lambert Journal: Am J Ophthalmol Date: 2014-08-13 Impact factor: 5.258
Authors: Marc H Levin; Gregory T Armstrong; Julian H Broad; Robert Zimmerman; Larissa T Bilaniuk; Tamara Feygin; Yimei Li; Grant T Liu; Michael J Fisher Journal: Br J Ophthalmol Date: 2015-08-20 Impact factor: 4.638
Authors: Katherine E Warren; Tina Y Poussaint; Gilbert Vezina; Darren Hargrave; Roger J Packer; Stewart Goldman; Patrick Y Wen; Ian F Pollack; David Zurakowski; Larry E Kun; Michael D Prados; Stefan Rutkowski; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2013-04-26 Impact factor: 3.167
Authors: Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: M Votruba; S Leary; N Losseff; S S Bhattacharya; A T Moore; D H Miller; I F Moseley Journal: Neuroradiology Date: 2000-03 Impact factor: 2.804
Authors: Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery Journal: J Neuroophthalmol Date: 2017-09 Impact factor: 3.042
Authors: Robert A Avery; Awais Mansoor; Rabia Idrees; Carmelina Trimboli-Heidler; Hiroshi Ishikawa; Roger J Packer; Marius George Linguraru Journal: Neurology Date: 2016-11-04 Impact factor: 9.910
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Jared M Pisapia; Hamed Akbari; Martin Rozycki; Jayesh P Thawani; Phillip B Storm; Robert A Avery; Arastoo Vossough; Michael J Fisher; Gregory G Heuer; Christos Davatzikos Journal: Neurooncol Adv Date: 2020-08-01